CN114685457B - 一种恩扎鲁胺光亲和探针及其制备方法 - Google Patents
一种恩扎鲁胺光亲和探针及其制备方法 Download PDFInfo
- Publication number
- CN114685457B CN114685457B CN202210405469.8A CN202210405469A CN114685457B CN 114685457 B CN114685457 B CN 114685457B CN 202210405469 A CN202210405469 A CN 202210405469A CN 114685457 B CN114685457 B CN 114685457B
- Authority
- CN
- China
- Prior art keywords
- enza
- reaction
- dayne
- anguang
- affinity probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000523 sample Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 206010060862 Prostate cancer Diseases 0.000 claims description 16
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 238000006482 condensation reaction Methods 0.000 claims description 8
- 238000004809 thin layer chromatography Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000005086 pumping Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 abstract description 15
- 229960004671 enzalutamide Drugs 0.000 abstract description 15
- 230000009471 action Effects 0.000 abstract description 9
- 239000003068 molecular probe Substances 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 4
- 238000005481 NMR spectroscopy Methods 0.000 abstract description 3
- 230000019491 signal transduction Effects 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 230000000694 effects Effects 0.000 description 9
- 102000001307 androgen receptors Human genes 0.000 description 8
- 108010080146 androgen receptors Proteins 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108010026552 Proteome Proteins 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000003596 drug target Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000006853 reporter group Chemical group 0.000 description 4
- VAKXPQHQQNOUEZ-UHFFFAOYSA-N 3-[4-[[bis[[1-(3-hydroxypropyl)triazol-4-yl]methyl]amino]methyl]triazol-1-yl]propan-1-ol Chemical compound N1=NN(CCCO)C=C1CN(CC=1N=NN(CCCO)C=1)CC1=CN(CCCO)N=N1 VAKXPQHQQNOUEZ-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100028292 Aladin Human genes 0.000 description 1
- 101710065039 Aladin Proteins 0.000 description 1
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003936 androgen receptor antagonist Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- -1 small molecule compounds Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- High Energy & Nuclear Physics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种恩扎鲁胺光亲和探针及其制备方法,涉及分子探针技术领域。本发明提供的恩扎鲁胺光亲和探针为鉴别恩扎鲁胺在治疗肿瘤中的作用靶点及其找出其作用机制提供了较为有力的援助,对了解这些信号传导途径并去确定未来的直接结合靶标将非常有意义。本发明制备出了恩扎鲁胺光亲和探针,利用核磁共振检测NMR测定其结构,结果与预期合成目标产物一致,可用于后续生物活性的检测与生物靶点鉴定工作。
Description
技术领域
本发明属于药物设计及合成领域,涉及一种新型恩扎鲁胺光亲和探针的制备方法。
背景技术
前列腺癌是男性生殖系肿瘤中非常重要的一种,在欧美常见恶性肿瘤中居第二位,而在美国前列腺发病率在所有恶性肿瘤中居第一位,死亡率居第二位。我国前列腺癌患者的发病率虽远低于西方国家,但近年来随老龄化增加呈显著增长趋势。由于雄激素在前列腺和前列腺癌的发展中起到举足轻重的作用,因此雄激素受体成为系统性治疗前列腺癌的基本靶标。
恩杂鲁胺(Enzalutamide)是由美国Medivation公司和日本安斯泰来(Astellas)公司合作开发新一代抗雄激素药物,于2012年和2013年分别被美国FDA和欧洲药品管理局批准上市,可用于治疗已扩散或复发的晚期(转移性)男性去势抵抗性前列腺癌(Castration-Resistant Prostate Cancer)。
恩扎鲁胺是一种新型结构非甾体类雄激素受体拮抗剂,具有如下结构:
恩扎鲁胺是与雄激素受体的结合能力增强,不会引发激动作用。
临床研究显示,其能延长转移性前列腺癌患者的总存活期达4.8个月,但存在一些不良反应,包括虚弱/疲劳,背痛,腹泻,关节痛,潮热,外周血水肿,肌肉骨骼痛,头痛,上呼吸道感染,肌肉无力,眩晕,失眠,下呼吸道感染,脊髓压迫症和马尾神经综合征,血尿,感觉异常,焦虑和高血压等。
为了对恩扎鲁胺的作用机制作一个深入的研究,进而为通过恩扎鲁胺结构针对性改造,同时为了尽早可以发现恩扎鲁胺分子结构导致潜在的缺陷,例如某些结构导致的毒副作用等,发现恩扎鲁胺分子在蛋白组层面的作用靶点进行明确化是非常有必要的。在生物体内,小分子化合物通过结合大分子靶标,可在基因组,转录组,蛋白质组和代谢组等各个层面引起表型变化。在这大多数情况下,大分子靶标通常会作为靶点蛋白,即与小分子起相互作用的蛋白质,这是因为蛋白质充当了细胞功能的主要执行者。
药物靶点的鉴定方法策略可分为两大类,第一类称为正向策略,它确定药物靶点的根据是药物引起的表型变化或者是依靠与之相关的已知信号通路和作用网络进行推测,它的方法包括差异基因组学/蛋白质组学分析,细胞形态分析差异等。第二类则是逆向策略,它则是以小分子药物为起点筛选靶点蛋白,包括化学蛋白质组学,化学基因组学和生物物理学等方法。
本发明所提供的探针用于逆向策略中的化学蛋白质组学方法。化学蛋白质组学是药物靶标鉴定最为常用的方法,他也被称作基于亲和性蛋白质组分析。
化学蛋白质组学技能的核心要素便是分子探针。分子探针的本质是将活性分子骨架和报告基团通过化学合成的手段,二者连接结合,组成的活性分子衍生物。报告基团就是可以特异性标记和富集相对应的蛋白质的特殊官能团,报告基团一般是固相介质、荧光或者生物素。
当活性分子骨架与报告基团连接成功后,活性分子的骨架端结构可以结合其对应的靶点蛋白,然后就可以对报告基团相连的活性分子和靶点蛋白结合的产物进行标记和富集,完成对靶点蛋白的富集、提取、洗脱和酶解,最后可以用质谱对该蛋白进行鉴定操作。
在最初的时候,当时的研究方案是用惰性树脂通过化学合成的方法与药物分子相结合而固定,这些惰性树脂采用的材料一般为可与生物相容的磁珠或者琼脂糖凝胶,这些树脂即可“钓取”与蛋白质组中能与其相互作用的蛋白质。这些固定化小分子的设计便是分子探针的最经典的设计策略。但是这种早期设计存在非常大的缺陷,因为化合物的活性非常容易受到影响,若是引入空间位阻较大的亲和标签,将很容易导致前者的活性降低甚至消失。因此需要找到新的方法来克服弥补这一经典方法的不足之处。
生物正交化学反应的发展有效缓解了上述的问题,最近以来应用最为广泛的靶点鉴定策略之一便是在引入生物正交反应基团到药物分子骨架之上。通过有机合成引入光亲和基团和生物正交基团,使修饰后的分子对原来的化合物的活性干扰较小,即可结合药物对应的靶点蛋白,结合的环境可以是活细胞或是细胞裂解液中,加大了灵活性和准确性。随后利用点击反应再将叠氮修饰的报告基团(生物素或荧光)连接到探针-靶标蛋白复合物上,最后就可以对靶标进行检测、富集和鉴定。
发明内容
本发明的目的是克服现有技术中不足,提供一种恩扎鲁胺光亲和探针。
根据本发明的第一个方面,本发明提供了一种式(I)结构的化合物Enza-Dayne,
根据本发明的第二个方面,发明提供了一种式(I)结构的化合物Enza-Dayne的用途,用于作为恩扎鲁胺光亲和探针。
根据本发明的第三个方面,本发明提供了一种式(I)结构的化合物Enza-Dayne的用途,用于制备治疗癌症药物中的用途;优选地,所述癌症为前列腺癌,更优选为LnCap细胞的前列腺癌。实验结果表明,本发明式(I)结构的化合物Enza-Dayne不仅可以用于恩扎鲁胺光亲和探针,标记标记重组雄激素受体(Androgen receptor,AR)蛋白,而且可以前列腺癌LnCap细胞增殖,起到抗癌效果。
根据本发明的第四个方面,本发明提供了一种式(I)结构的化合物Enza-Dayne的制备方法,由Enza-COOH与Dayne-NH2进行脱水缩合反应形成酰胺键,反应方程式如下:
优选地,所述缩合反应中加入缩合剂,本领域普通技术人员可以选择常规酰胺键形成的缩合剂,例如EDCI/HOBt体系,通常同时加入有机碱如DIEPA。
优选地,所述缩合反应中采用TLC或LC-MS检测反应进程,确认反应体系中不存在Enza-COOH,即表示反应完全。
优选地,所述缩合反应中反应完全后,将反应液用液氮冷冻,用冷冻干燥机除去溶剂。
本发明还提供的所述的式(I)结构的化合物Enza-Dayne作为恩扎鲁胺光亲和探针在生物活性的检测与生物靶点鉴定中的应用。
与现有技术相比,本发明所能达到的技术效果包括:
本发明提供的式(I)结构的恩扎鲁胺光亲和探针Enza-Dayne对于临床前列腺癌治疗药物恩扎鲁胺的作用靶点的鉴定非常关键。随着化学蛋白质组学、生物信息学、网络药理学等新兴学科和技术的交叉融合与不断完善,将会有更多、更新的药物靶标鉴定新方法、新技术出现,关于小分子药潜在靶标蛋白的报道也会越来越多,将持续推动小分子药物药理机制和副作用产生原因的研究。
对于小分子药物探针的设计与合成而言,本发明提供的一种恩扎鲁胺光亲和探针为恩扎鲁胺的作用靶点及其找出其作用机制提供了较为有力的援助,对了解这些信号传导途径并去确定未来的直接结合靶标将非常有意义。
本发明提供的制备一种恩扎鲁胺光亲和探针的方法,利用小分子恩扎鲁胺为基本原料,成功制备出了上述结构的恩扎鲁胺光亲和探针,使用薄层色谱分析法(TLC)监测反应的进行,得到粗产物后,进行液相色谱-质谱联用以(LC-MS)检测粗产物中的预期产物,得到其预期质谱峰和液相峰。然后对粗产物进行分离纯化,再采用高效液相色谱(HPLC)对目标产物提取分离。然后利用核磁共振检测NMR以测定其结构,结果与预期合成目标产物一致,可用于后续生物靶点鉴定工作。
附图说明
图1为本发明实施例1提供的制备式(1)结构的恩扎鲁胺光亲和探针1H-NMR检测的检测结果。
图2为本发明实施例1提供的制备式(1)结构的恩扎鲁胺光亲和探针13C-NMR检测的检测结果。
图3为恩扎鲁胺光亲和探针标记重组雄激素受体蛋白图。
图4为恩扎鲁胺竞争性标记组雄激素受体蛋白图。
图5为恩扎鲁胺光亲和探针抑制前列腺癌LnCap细胞增殖图。
具体实施方式
实施例1:恩扎鲁胺光亲和探针的合成
化合物Dayne-NH2根据参考文献的方法(Angew.Chem.Int.Ed,2013,52,8551)在本实验室合成;化学合成使用的试剂分别从Sigma-Aldrich、TCI、MedChemExpress或Aladdin等公司购买而得。
干燥的烧瓶中依次加入Enza-COOH(451mg,1mmol),EDCI(230mg,1.2mmol)和HOBt(180mg,1.2mmol),抽换氮气,加入5mL无水N,N-二甲基甲酰胺(DMF),室温搅拌10分钟后,置于冰浴。冰浴下加入溶于3mL无水DMF的3-(丁-3-炔基)-3-(2-胺基乙基)-3H-双吖丙啶(Dayne-NH2)(151mg,1.1mmol),缓慢升至室温并搅拌反应20小时,薄层层析(TLC)检测。反应完全后,加入50mL乙酸乙酯,再分别用10mL 10%HCl,20mL饱和碳酸氢钠溶液、20mL饱和食盐水洗涤。最后用无水硫酸钠干燥,并通过柱层析分离得到分子探针Enza-Dayne(白色固体,534mg,93.6%收率)。
化合物结构信息(图1~图2):
1H-NMR(500MHz,exists as isomers):8.30(t,1H,J=8.4Hz),7.97(d,1H,J=8.0,1.2Hz),7.84(dd,1H,J=8.0Hz),7.27(s,1H),7.21(dd,1H,J=8.2,1.2Hz),6.82(t,1H,J=8.4Hz),3.40(m,2H),2.09(m,2H),2.07(m,5H),1.64(s,6H).
13C-NMR(125MHz,exists as isomers):179.75,174.40,162.06,161.45,159.45,139.25,139.17,136.80,135.31,133.59,133.37,133.35,132.10,127.07,126.95,126.25,126.23,122.54,122.45,118.11,117.90,114.68,110.47,82.53,69.43,66.63,35.08,32.46,32.20,29.70,26.79,23.88,13.22.
HRMS-ESI calc’d.for C27H23F4N6O2S+[M+H]+:571.1534;Found:571.1602.
实施例2:恩扎鲁胺光亲和探针Enza-Dayne标记重组雄激素受体(Androgenreceptor,AR)蛋白。
将体外重组表达的AR蛋白(MCE,HY-P72088)在PBS中稀释至0.1mg/mL。每个样品中,加入20μLAR蛋白和不同浓度的探针Enza-Dayne室温孵育1小时后,冰浴条件下365nm紫外光照射15分钟。随后每个样品中分别加入0.2μL的羧基四甲基罗丹明-叠氮TAMRA-N3(10mM在DMSO中的储液)、CuSO4(100mM在水中的储液)、三(3-羟丙基三唑甲基)胺THPTA(10mM在水中的储液)和抗坏血酸钠(100mM在水中的储液),室温避光孵育1小时。加入5μL5×SDS上样缓冲液并且在95℃煮沸15分钟终止反应。将样品施加到10%Bis-tris变性凝胶并且用FUJIFILM FLA 9000plus荧光成像系统进行凝胶荧光扫描。如图3所示,探针Enza-Dayne可浓度依赖的标记重组AR蛋白,在1M时探针标记即达到饱和。
实施例3:恩扎鲁胺竞争性标记重组AR蛋白。
将体外重组表达的AR蛋白(MCE,HY-P72088)在PBS中稀释至0.1mg/mL。每个样品中,加入20μL AR蛋白和不同浓度的恩扎鲁胺,随后加入1M探针Enza-Dayne室温孵育1小时后,冰浴条件下365nm紫外光照射15分钟。随后每个样品中分别加入0.2μL的TAMRA-N3(10mM在DMSO中的储液)、CuSO4(100mM在水中的储液)、THPTA(10mM在水中的储液)和抗坏血酸钠(100mM在水中的储液),室温避光孵育1小时。加入5μL 5×SDS上样缓冲液并且在95℃煮沸15分钟终止反应。将样品施加到10%Bis-tris变性凝胶并且用FUJIFILM FLA 9000plus荧光成像系统进行凝胶荧光扫描。如图4所示,恩扎鲁胺可以浓度依赖地抑制探针Enza-Dayne标记重组AR蛋白。
实施例5:恩扎鲁胺光亲和探针Enza-Dayne抑制前列腺癌细胞增殖。
通过CellTiter发光法细胞活力检测试剂盒评价恩扎鲁胺光亲和探针Enza-Dayne对前列腺癌LnCap细胞增殖的影响。
由图5可见,恩扎鲁胺光亲和探针Enza-Dayne对前列腺癌LnCap细胞有显著的抗增殖活性,IC50值为12.8M。证明本发明所述恩扎鲁胺光亲和探针保持了恩扎鲁胺的抗肿瘤活性。
需要说明的是,对于包括恩扎鲁胺在内的广大具有副作用或脱靶效应的小分子药物,对它们的作用靶点进行鉴定仍然是非常有必要的。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (8)
1.一种式(I)结构的化合物Enza-Dayne,
式(I)。
2.一种权利要求1所述的式(I)结构的化合物Enza-Dayne的用途,用于作为恩扎鲁胺光亲和探针。
3.一种权利要求1所述的式(I)结构的化合物Enza-Dayne的用途,用于制备治疗癌症药物中的用途,所述癌症为前列腺癌。
4.一种式(I)结构的化合物Enza-Dayne的制备方法,由Enza-COOH与Dayne-NH2进行脱水缩合反应形成酰胺键,反应方程式如下:
。
5.根据权利要求4所述的方法,其特征在于:所述缩合反应中加入缩合剂。
6.根据权利要求4所述的方法,其特征在于:所述缩合反应中采用TLC或LC-MS检测反应进程,确认反应体系中不存在Enza-COOH,即表示反应完全。
7.根据权利要求4所述的方法,其特征在于:所述缩合反应中反应完全后,将反应液用液氮冷冻,用冷冻干燥机除去溶剂。
8.根据权利要求4所述的方法,其特征在于:干燥的烧瓶中依次加入Enza-COOH,EDCI和HOBt ,抽换氮气,加入无水N,N-二甲基甲酰胺,室温搅拌后,置于冰浴;冰浴下加入溶于无水DMF的Dayne-NH2,缓慢升至室温并搅拌反应,薄层层析检测;
反应完全后,加入乙酸乙酯,再分别用HCl,饱和碳酸氢钠溶液、饱和食盐水洗涤;最后用无水硫酸钠干燥,并通过柱层析分离得到化合物Enza-Dayne。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210405469.8A CN114685457B (zh) | 2022-04-18 | 2022-04-18 | 一种恩扎鲁胺光亲和探针及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210405469.8A CN114685457B (zh) | 2022-04-18 | 2022-04-18 | 一种恩扎鲁胺光亲和探针及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114685457A CN114685457A (zh) | 2022-07-01 |
CN114685457B true CN114685457B (zh) | 2024-02-27 |
Family
ID=82143516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210405469.8A Active CN114685457B (zh) | 2022-04-18 | 2022-04-18 | 一种恩扎鲁胺光亲和探针及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114685457B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113149962A (zh) * | 2021-03-16 | 2021-07-23 | 无锡海伦生物科技有限公司 | 含有光亲和基团双吖丙啶的探针分子的制备方法及应用 |
CN113480558A (zh) * | 2021-08-05 | 2021-10-08 | 南京市第一医院 | 一种雄激素受体小分子荧光探针及其制备方法和应用 |
-
2022
- 2022-04-18 CN CN202210405469.8A patent/CN114685457B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113149962A (zh) * | 2021-03-16 | 2021-07-23 | 无锡海伦生物科技有限公司 | 含有光亲和基团双吖丙啶的探针分子的制备方法及应用 |
CN113480558A (zh) * | 2021-08-05 | 2021-10-08 | 南京市第一医院 | 一种雄激素受体小分子荧光探针及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114685457A (zh) | 2022-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106831489A (zh) | 苯环丙胺酰腙类化合物、制备方法及其应用 | |
Li et al. | Discovering novel chemical inhibitors of human cyclophilin A: virtual screening, synthesis, and bioassay | |
CN110627801B (zh) | 一类hdac抑制剂及其用途 | |
US5854409A (en) | Pro-thiol aryl azide labelling of nucleic acids | |
CN106632271A (zh) | 具有抗肿瘤活性的厄洛替尼衍生物及其制备方法和应用 | |
CN108341781B (zh) | 植物次生代谢产物生物合成途径中相关酶类的解析方法 | |
PL194932B1 (pl) | Nowe pochodne izoksazolu i amidu kwasu krotonowego, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie nowych pochodnych izoksazolu i amidu kwasu krotonowego | |
CN114621310B (zh) | 基于雷公藤红素的靶向Prdx2降解剂及其制备方法与医药用途 | |
Chen et al. | Design, synthesis and identification of N, N-dibenzylcinnamamide (DBC) derivatives as novel ligands for α-synuclein fibrils by SPR evaluation system | |
CN112569365A (zh) | 一种核酸适配体药物偶联物及其制备方法和用途 | |
CN107400070B (zh) | 双胍类探针及其制备方法 | |
JP6461306B2 (ja) | インサイチュで自己組織化した、毒性のあるrna阻害剤 | |
CN114685457B (zh) | 一种恩扎鲁胺光亲和探针及其制备方法 | |
CN114685463A (zh) | 一种异鼠李素光亲和探针及其合成方法和应用 | |
CN109369620B (zh) | 吡啶类化合物及其制备方法与抗胃癌应用 | |
CN113582864B (zh) | Prmti型甲基转移酶抑制活性化合物及其制备与应用 | |
CN108794398B (zh) | 具有荧光的选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用 | |
CN113620847B (zh) | 萘磺酰类化合物、其制备方法和应用 | |
JP6021148B2 (ja) | Lst−1及び/又はlst−2によって輸送される化合物 | |
CN108761083B (zh) | 一种生物素标记的依布硒啉探针及其制备方法和应用 | |
US20020103349A1 (en) | Drug-oligonucleotides chimeric molecules | |
CN107446012B (zh) | 一类肿瘤荧光显像剂及制备和应用 | |
CN116082308B (zh) | 一种降解剂及其制备方法和应用 | |
Yan et al. | Neamine-heterocycle conjugates as potential anti-HIV agents | |
CN114956997B (zh) | 香草扁桃酸半抗原衍生物及其合成方法,香草扁桃酸抗原及其制备方法,抗体及试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |